Richard L. Schilsky, MD
The growing use of genetic biomarker tests to screen, monitor, diagnose, and treat patients with cancer has the potential to improve outcomes and reduce costs (Table)
, but payment systems for covering and reimbursing for these tests have fallen behind the times.
Alvin Martin, MD
Source: Schneider JE, Sidhu MK, Doucet C, et al. Economics of cancer biomarkers. Per Med. 2012;8:829-837.